Aureogen Biosciences, Inc.

Kalamazoo, MI 49009

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $3.89MM
First Award Date 09/30/04
Most Recent Award Date 02/01/12

Key Personnel

Last Name Name Awards Contact
Elhammer Ake P Elhammer 10

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 02/01/12 - 01/31/13

DESCRIPTION (provided by applicant): The continuing increase in the number of surgery, transplantation, cancer and other immunocompromized patients, that need treatment for fungal infections, together with the fact that only one new class of antifungal therapeutics has been introduced to the market in over 30 years has created an immediate need ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 02/01/11 - 01/31/12

DESCRIPTION (provided by applicant): The continuing increase in the number of surgery, transplantation, cancer and other immunocompromized patients, that need treatment for fungal infections, together with the fact that only one new class of antifungal therapeutics has been introduced to the market in over 30 years has created an immediate need ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 04/01/09 - 03/31/11

DESCRIPTION (provided by applicant): HCV infections are a prevalent and growing health problem. It is estimated that as many as 2% of the US population, and 2.5% of the population world-wide, are infected by HCV. The disease currently causes 15,000 deaths/year in US alone, a number that is predicted to increase three-fold by 2010. Treatment opti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 06/13/08 - 05/31/10

DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant bacterial infections has increased drastically in recent years. What started as a problem primarily associated with hospital-acquired Enterococcus infections, has not only moved into the general community, but also grown to include a number of widesprea...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/08 - 05/31/10

DESCRIPTION (provided by applicant): There is an immediate need for novel drugs for the treatment of fungal infections, (antibiotics resistant) bacterial infections, and cancer. Cyclic peptides constitute a class of compounds that have made crucial contributions to the treatment of these diseases. Although cyclic peptides can be very efficient d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 04/01/08 - 03/31/09

DESCRIPTION (provided by applicant): HCV infections are a prevalent and growing health problem. It is estimated that as many as 2% of the US population, and 2.5% of the population world-wide, are infected by HCV. The disease currently causes 15,000 deaths/year in US alone, a number that is predicted to increase three-fold by 2010. Treatment opti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 07/01/07 - 06/30/09

DESCRIPTION (provided by applicant): The number of patients treated for antibiotics-resistant infections has increased drastically in recent years. What started as a problem primarily associated with hospital-acquired Enterococcus infections, has not only moved into the general community, but also grown to include a number of widespread and seri...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/07 - 05/31/08

DESCRIPTION (provided by applicant): There is an immediate need for novel drugs for the treatment of fungal infections, (antibiotics resistant) bacterial infections, and cancer. Cyclic peptides constitute a class of compounds that have made crucial contributions to the treatment of these diseases. Although cyclic peptides can be very efficient d...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/06 - 05/31/07

DESCRIPTION (provided by applicant): There is an immediate need for novel drugs for the treatment of fungal infections, (antibiotics resistant) bacterial infections, and cancer. Cyclic peptides constitute a class of compounds that have made crucial contributions to the treatment of these diseases. Although cyclic peptides can be very efficient d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 09/30/05

DESCRIPTION (provided by applicant): There is an immediate need for efficient, novel antifungal drugs. The fungus Aureobasidium pullulans produces a cyclic peptide know as Aureobasidin A (AbA) which is a very potent, fungicidal drug that is currently barred from commercialization due to a requirement for modifications involving complex and expe...

Load More